Whitepaper: Development of prophylactic and therapeutic #vaccines using the ISCOMATRIX ® adjuvant
CSL Limited have just published their latest whitepaper "Development of prophylactic and therapeutic #vaccines using the ISCOMATRIX ® adjuvant".
Don’t miss this unique opportunity to download their white paper and learn about the novel adjuvants as technology platforms, with particular reference to the ISCOMATRIX® adjuvant.
The ISCOMATRIX adjuvant has several key features and properties required for use in both prophylactic and therapeutic human vaccines. The mechanism of action of the ISCOMATRIX adjuvant is being elucidated although further work is required to ascertain the exact mechanisms so as to maximize its safe and effective use in humans.
Debbie Drane, Senior Vice President of R&D at CSL Limited, will deliver the presentation on novel adjuvants as technology platforms at the 13th World Vaccine Congress Lyon congress, Europe’s most prestigious vaccine industry and governmental congress for Pharma, biotech and service providers.
If you want to learn more about how to develop and commercialize your vaccine pipelines, register today to attend the World #Vaccine Congress Lyon!